Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results
November 3, 2015 4:06 PM ESTTotal Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk Hereditary Cancer Company Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidance
SALT LAKE CITY, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2016, provided an update on recent business highlights, maintained its fiscal year 2016 financial guidance and provided fiscal second-quarter 2016 financial guidance.
"We were very... More
